Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies of Vaccine-Preventable Diseases Influencing My Practice Following IDWeek 2021—Rapid Recap by Martin Mahoney, MD, PhD

Source: IDWeek 2021: Clinical Impact of New Data*
September 29 - October 3, 2021; Virtual
Hear unique insights from expert faculty on important studies from IDWeek 2021, including new data on vaccines for pneumococcal disease, respiratory syncytial virus, herpes zoster, and influenza.
Martin C. Mahoney, MD, PhD
Released: November 11, 2021

Information on this Educational Activity

Faculty

Martin C. Mahoney, MD, PhD

Professor of Oncology
Department of Internal Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Martin C. Mahoney, MD, PhD, has disclosed that he has received consulting fees from Merck, Pfizer, and Sanofi; fees for non-CME/CE services from GlaxoSmithKline, Merck, Pfizer, and Sanofi; and other financial or material support from Pfizer.

Program Medium

This program has been made available online.

Related Content

Expert faculty discuss guideline recommendations for nontuberculous mycobacterial lung disease (NTM-LD), from Clinical Care Options (CCO)

Keira A. Cohen, MD
Program Director person default David E. Griffith, MD Princy N. Kumar, MD, FIDSA, MACP Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Pharmacists: 1.0 contact hour (0.1 CEUs) Released: November 19, 2021 Expired: November 18, 2022
Emergence of New Guidelines: NTM Lung Disease in 2021
How can we reduce the time to diagnosis of NTM-LD and linkage to care?
How do you decide to start (or not start) treatment for NTM-LD?
What do you monitor for and how often during NTM-LD treatment?
How do you approach treatment-refractory NTM-LD?

Clinical Care Options (CCO): Dr. Paul Auwaerter discusses the latest pneumococcal vaccine data and the impact on his practice, presented at IDWeek 2021

Paul G. Auwaerter, MD Released: November 19, 2021

From Clinical Care Options (CCO) and Dr. Dalilah Restrepo: guidance on use of the recombinant zoster vaccine (RZV) to prevent shingles complications

person default Dalilah Restrepo, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 10, 2021 Expired: November 9, 2022

Download key slides on guidance and CDC recommendations on vaccination to prevent shingles and its complications in the COVID-19 era.

person default Dalilah Restrepo, MD Released: November 10, 2021
Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue